Coronary disease & ACSGuideline or statement
Therapies leading to coronary atherosclerosis plaque regression: a scientific statement of the European Association of Preventive Cardiology, the European Association of Cardiovascular Imaging of the ESC, the ESC Working Group on Atherosclerosis and Vascular Biology, and the ESC Working Group on Cardiovascular Pharmacotherapy Part 2—drugs’ specific effect on atherosclerosis
- Scientific statement
Recommendations
As issued by the authors
Statins, particularly at higher doses, have the most extensive data supporting their effect on atherosclerosis, mainly fibro-lipidic plaque volume regression
Emerging data suggest non-statin lipid-lowering drugs and anti-inflammatory therapies may also affect the natural history of atherosclerosis
The absolute change in coronary plaque volume is generally limited
Original publication
Therapies leading to coronary atherosclerosis plaque regression: a scientific statement of the European Association of Preventive Cardiology, the European Association of Cardiovascular Imaging of the ESC, the ESC Working Group on Atherosclerosis and Vascular Biology, and the ESC Working Group on Cardiovascular Pharmacotherapy Part 2—drugs’ specific effect on atherosclerosis. Eur J Prev Cardiol. Published 6 November 2025. doi:10.1093/eurjpc/zwaf654
Summarised from the published abstract; every number is checked against it